Companies / BOC Sciences / Sabatolimab
BOC Sciences

Sabatolimab | BOC Sciences

Sabatolimab is a humanized monoclonal antibody directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Sabatolimab has been approved for the treatment of adult patients with myelodysplastic syndromes (MDS).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.